FY2026 EPS Estimates for Sanofi Reduced by Erste Group Bank

Sanofi (NASDAQ:SNY) – Equities research analysts at Erste Group Bank decreased their FY2026 earnings estimates for Sanofi in a research note issued on Wednesday, March 4th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $4.92 per share for the year, down from their previous forecast of $4.96. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Erste Group Bank also issued estimates for Sanofi’s FY2027 earnings at $5.21 EPS.

A number of other equities research analysts have also recently issued reports on SNY. HSBC restated a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and a consensus price target of $62.67.

Sanofi Stock Down 0.4%

Sanofi stock opened at $44.35 on Monday. The stock has a market cap of $108.17 billion, a P/E ratio of 12.32, a P/E/G ratio of 1.15 and a beta of 0.45. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. Sanofi has a twelve month low of $43.34 and a twelve month high of $60.12. The company’s 50-day moving average price is $47.23 and its two-hundred day moving average price is $48.40.

Institutional Investors Weigh In On Sanofi

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brighton Jones LLC boosted its stake in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares during the period. AQR Capital Management LLC raised its holdings in Sanofi by 107.2% in the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after acquiring an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Sanofi by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after acquiring an additional 752 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after acquiring an additional 347 shares during the period. Finally, Moors & Cabot Inc. grew its holdings in shares of Sanofi by 3.9% during the 2nd quarter. Moors & Cabot Inc. now owns 8,307 shares of the company’s stock worth $401,000 after purchasing an additional 313 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.